Groupe: Sylvie Bay
Groupe : Carbohydrates et Glycoconjugués
Synthetic carbohydrate-based conjugates as Shigella vaccine components: design, synthesis, selection and process validation
A synthetic carbohydrate-based conjugate vaccine ready for a clinical trial
Protein conjugates for the diagnosis of Alzheimer’s disease
Development of specific imaging nanoprobes against intracerebral targets is a challenging field of research, particularly for the diagnosis of neurodegenerative diseases. Probes based on camelid single-domain antibody-fragments (VHHs or nanobodies) are promising tools due […]
At the forefront of the rising fields of Chemical and Synthetic Biology, CarbUniVax is a multidisciplinary project sitting at the frontier between Glycosciences and Vaccinology. A multidisciplinary strategy is proposed that challenges ambitious goals […]
Synthesis of peptide and protein conjugates towards novel therapeutics and/or diagnostic tools
Synthetic peptides and conjugates thereof as potential antivirals (col. H. Lortat-Jacob (CEA, Grenoble), D. Bonnaffé (ICMMO, Orsay) A bi-substrate synthetic glycopeptide resulting from the covalent linkage between a CD4 peptide mimetic and a heparan […]
Carbohydrates as targets of immunity: their synthesis, antibody recognition and use as key vaccine components
Synthetic oligosaccharides are designed and used to identify immunodominant epitopes of bacterial polysaccharide antigens. Conjugates of the most promising oligosaccharides are developed as potential vaccines. Focus is on diarrheal diseases. Shigellosis – bacillary […]
Use of nanobodies for imaging plaques and tangles in Alzheimer’s disease
Homodimeric VHHs offer new perspectives for in vivo immunodiagnosis. Because of their small size of about 12-14 kDa, VHHs rapidly pass the renal filter, which has a cutoff of about 60 kDa, resulting in […]
Protected tetrasaccharides, their preparation and their use in the synthesis of bacterial oligosaccharides
2021Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study., Lancet Infect Dis 2021 04; 21(4): 546-558.
2021Exploratory N-Protecting Group Manipulation for the Total Synthesis of Zwitterionic Shigella sonnei Oligosaccharides., Chemistry 2021 Mar; 27(18): 5694-5711.
2021Convergent Chemoenzymatic Strategy to Deliver a Diversity of Shigella flexneri Serotype-Specific O-Antigen Segments from a Unique Lightly Protected Tetrasaccharide Core., J Org Chem 2021 Feb; 86(3): 2058-2075.
2021Redirecting substrate regioselectivity using engineered ΔN123-GBD-CD2 branching sucrases for the production of pentasaccharide repeating units of S. flexneri 3a, 4a and 4b haptens., Sci Rep 2021 Jan; 11(1): 2474.
2019Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human., Hum Vaccin Immunother 2019 ; 15(6): 1338-1356.
2018ADP-heptose is a newly identified pathogen-associated molecular pattern of Shigella flexneri., EMBO Rep 2018 12; 19(12): .
2018Bacteriophage Sf6 Tailspike Protein for Detection of Shigella flexneri Pathogens., Viruses 2018 08; 10(8): .
2017Dirhamnolipids secreted from Pseudomonas aeruginosa modify anjpegungal susceptibility of Aspergillus fumigatus by inhibiting β1,3 glucan synthase activity., ISME J 2017 07; 11(7): 1578-1591.
2016Heparan sulfate differentially controls CXCL12α- and CXCL12γ-mediated cell migration through differential presentation to their receptor CXCR4, Sci Signal 2016 Nov;9(452):ra107.
2016CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge, Sci Rep 2016 Oct;6:34829.
+Voir la liste complète de publications
Phone: + 33 (0) 1 40 61 38 20
Unité de Chimie des Biomolécules
25-28 Rue du Docteur Roux